TL;DR: A 2026 pilot study in The British Journal of Psychiatry tested psilocybin-assisted therapy in 21 adult females with anorexia nervosa and found lower Eating Disorder Examination (EDE) symptom scores through 6 months, with large individual variation and no placebo-controlled comparison. Key Findings Single-arm pilot study: Researchers enrolled 21 adult females with anorexia nervosa and …
TL;DR: A 2025 study in Journal of the American Chemical Society used photochemistry to turn amino-acid-linked tryptamines into azocinoindoles that activated serotonin 5-HT2A signaling while suppressing the mouse head-twitch response. Key Findings C4 indole route: The method used light-induced cyclization to functionalize the indole ring at the C4 position. Amino-acid inputs: Amino acids were coupled …
TL;DR: A 2026 exploratory study in Translational Psychiatry found blood DNA methylation changes after 25 mg psilocybin in detoxified alcohol use disorder patients, including findings near TLE4 and RASGRP4, but the small trial did not establish a definitive AUD biomarker. Key Findings 37 AUD patients: The methylation analysis used a randomized, double-blind psilocybin trial completed …
TL;DR: A 2026 trial in Journal of Psychopharmacology found that repeated supervised psilocybin sessions reduced Yale-Brown Obsessive Compulsive Scale (YBOCS) scores, a standard measure of obsession and compulsion severity, in 15 adults with OCD. Key Findings 73.3% met responder criteria: At the end of the 8-week treatment, 11 of 15 participants had at least a …
TL;DR: A 2026 Scientific Reports study of 6,805 English-language media reports found that psychedelic-treatment coverage for depression and PTSD used more positive tone than antidepressant coverage, while antidepressant coverage used more risk and negative-emotion language. Key Findings 6,805 media reports: Researchers analyzed English-language newspaper coverage from 2017 to 2024 using LexisNexis and natural language processing. …
TL;DR: A 2026 randomized clinical trial in JAMA Network Open found that one supervised 30 mg/70 kg psilocybin dose plus cognitive behavioral therapy produced 40.5% six-month smoking abstinence versus 10.0% with a nicotine patch plus the same therapy. Key Findings 40.5% vs. 10% prolonged abstinence at 6 months: 17 of 42 psilocybin participants stayed biochemically …
TL;DR: A 2026 study in Psychopharmacology found that after 14 days of unpredictable chronic stress, a single 1-hour ayahuasca exposure restored sociability, reduced anxiety-like behavior, normalized cortisol, and rescued whole-brain BDNF in adult zebrafish within 24 hours. Key Findings 396 fish across 6 groups: Adult zebrafish were split into stressed and non-stressed groups, then exposed …
TL;DR: A 2026 exploratory study in Nature Communications found that a first 25 mg psilocybin dose in 28 psychedelic-naive adults increased electroencephalography (EEG), a scalp recording of brain electrical activity, entropy during the acute session and that entropy predicted one-month well-being change. Key Findings 28 psychedelic-naive adults: Participants received 1 mg psilocybin as a low-dose …
TL;DR: A 2026 randomized trial in The British Journal of Psychiatry found 6 ketamine infusions improved severe treatment-resistant depression, but curated music added no measurable benefit; higher mystical-experience scores still predicted the next session’s depression outcome. Key Findings MADRS fell 11.8 points by week 4: Scores dropped from 31.5 to 19.7 (d = 1.2, p …
Fluorinated Psilocin: The Sub-Hallucinogenic Breakthrough TL;DR: Chemists designed a new psilocin derivative with fluorine modifications that induces sub-hallucinogenic effects in mice, sidestepping the acute psychological effects of classic psychedelics while retaining therapeutic serotonin receptor activity. Psilocybin has emerged as a clinical darling—mounting evidence shows rapid relief for depression, anxiety, and cluster headaches. But there’s a …
